Skip to main content
TheraVet SA logo

TheraVet SA — Investor Relations & Filings

Ticker · ALVET ISIN · BE0974387194 LEI · 984500804EBR3F1EFF71 BR Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2023-07-11 Earnings Release
Country BE Belgium
Listing BR ALVET

About TheraVet SA

https://www.egeiro.com/

TheraVet SA is a veterinary biotechnology company specializing in the development and commercialization of treatments for osteoarticular diseases in companion animals. The company focuses on creating a portfolio of pharmaceutical products and solutions designed to manage bone and joint conditions, such as osteoarthritis. Its primary objective is to provide innovative therapeutic options to improve the mobility and quality of life for pets.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is titled "TheraVet provides an update on its 2023 half-year development and portfolio strategy" and explicitly states it provides the "half-year update on its development strategy." It details operational progress, product launches (BIOCERA-VET® COMBO-CLEAN in May), clinical program updates (Osteosarcoma, Equine, Non-Union), and includes a cash update as of June 30, 2023. Crucially, it announces the next financial update: "2023 Half-Year Results, on September 06, 2023." This content structure—a detailed operational and strategic review covering the first half of the year, often released shortly before or in lieu of the formal financial filing—is characteristic of an Interim/Quarterly Report (IR) or a Management Discussion & Analysis (MDA). Since it provides substantial operational detail and a cash position update, it leans towards a comprehensive report rather than just an Earnings Release (ER). Given the focus on the half-year period and the comprehensive nature of the update, the most appropriate classification is Interim / Quarterly Report (IR). It is not a formal 10-K (Annual Report) or a short announcement (RPA/RNS). H2 2023
2023-07-11 English
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is a press release dated June 15, 2023, providing an update on the company's Osteosarcoma Program progress (increase in participating centers) and participation in a scientific congress (ESVONC). It highlights operational achievements and product positioning rather than releasing formal periodic financial statements (like 10-K or IR) or announcing a dividend or management change. This type of operational/business update, often released outside of mandatory quarterly/annual filings, fits best under the general 'Regulatory Filings' (RNS) category, as it is a broad announcement of company activity that doesn't match the more specific categories like ER (Earnings Release), DIV (Dividend), or MANG (Management Change). Given the content is a news update, RNS is the most appropriate fallback. H1 2023
2023-06-15 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 99% confidence The document is a press release from TheraVet dated June 15, 2023, providing an update on their osteosarcoma program, participation in a veterinary oncology conference (ESVONC), and highlighting product details. It announces operational progress (increase in participating centers) and market engagement, which are typical components of an Earnings Release (ER) or a general business update. Since it focuses on operational milestones and recent events rather than comprehensive financial statements (like a 10-K or IR) or a formal call transcript, it best fits the 'Earnings Release' category, which covers initial announcements of periodical results and key highlights. Although it's not strictly financial results, these operational updates often accompany or substitute for the 'highlights' section of an ER. Given the context of a biotech company providing operational progress updates, ER is the most appropriate fit among the choices, as it is a scheduled update. It is not a 10-K (Annual Report), AR (Audit Report), CT (Call Transcript), or IR (Interim Report) as it lacks detailed financial statements. It is not an RPA because it is the substantive content itself, not just an announcement of another report.
2023-06-15 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release dated May 31, 2023, announcing the commercial launch of a new product, BIOCERA-VET COMBO-CLEAN. It details the product features and its availability. This type of announcement, which is a specific business update rather than a comprehensive financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV), fits best under the general category for significant corporate news that isn't strictly regulatory or financial reporting. Since it is a specific product launch announcement, it is not a standard Earnings Release (ER) or a general Regulatory Filing (RNS). Given the options, this is a specific corporate event announcement. It is not a standard financial filing (10-K, IR, MRQ). It is not a management change (MANG) or director dealing (DIRS). It is a specific business development announcement. While 'RNS' (Regulatory Filings) is a fallback, this reads like a standard press release detailing operational news. However, none of the codes perfectly capture a 'Product Launch Announcement'. Comparing it to the definitions, it is not a financing event (CAP), not an AGM/Voting event, not a legal update (LTR), and not a management report (MDA). It is a specific operational update. In the absence of a 'Product Launch' code, 'RNS' (General regulatory announcements and fallback category for miscellaneous filings) is the most appropriate general category for a non-standard, non-financial press release.
2023-05-31 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 99% confidence The document is a press release from TheraVet announcing the commercial launch of a new product, BIOCERA-VET® COMBO-CLEAN. It details the product features, its intended use (bone substitute with prolonged antibiotic release), and provides contact information for investors and press. This type of announcement, focusing on a specific business event (product launch) rather than periodic financial results (ER, IR, 10-K) or management changes (MANG), is best classified as a general business update or regulatory filing. Since it is a specific business announcement that doesn't fit the other specialized categories (like CAP, DIV, DIRS, etc.), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for significant, non-standard corporate news releases.
2023-05-31 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release dated May 04, 2023, announcing TheraVet's collaboration for a new clinical program assessing their product BIOCERA-VET in fracture complications. It details the study design, participating centers, and expected results timeline. This type of announcement, focusing on operational updates, clinical trials, and product development rather than mandatory financial reporting (like 10-K, ER, or IR), typically falls under general corporate news or regulatory announcements. Since it is not a formal financial report, a management change, a dividend notice, or a specific legal filing, it best fits the 'Regulatory Filings' (RNS) category as a general corporate announcement, or potentially 'LTR' if the clinical trial was mandated by a regulator, but RNS is the broader fit for press releases detailing operational progress not covered by other specific codes. Given the context of a company updating the market on clinical progress, RNS is the most appropriate general regulatory/corporate update category.
2023-05-04 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.